Short communication
Tonic analgesic effects of Δ9-tetrahydrocannabinol as measured with the formalin test

https://doi.org/10.1016/0014-2999(80)90134-XGet rights and content

Abstract

The analgesic effects of Δ9-tetrahydrocannabinol (THC), the psychoactive component of marihuana, were tested using the formalin test. Rats were treated with either THC (5 mg/kg or 10 mg/kg) or a placebo by gavage 4 h before the formalin test for analgesia was initiated. THC produced a highly significant analgesic effect against both phasic pain and tonic pain. THC is discussed as a model for the development of new analgesics or as a suitable analgesic if used with another potentiating drug.

References (8)

There are more references available in the full text version of this article.

Cited by (46)

  • Herbal biomolecules acting on central nervous system

    2022, Herbal Biomolecules in Healthcare Applications
  • Sex differences and the endocannabinoid system in pain

    2021, Pharmacology Biochemistry and Behavior
  • CB<inf>1</inf> cannabinoid receptor agonist mouse VD-hemopressin(α) produced supraspinal analgesic activity in the preclinical models of pain

    2018, Brain Research
    Citation Excerpt :

    In theory, phase I is generally considered to be due to direct stimulation of peripheral nociceptors, whilst phase II is a more complex peripherally and centrally mediated hypersensitivity of nociceptive circuitry (Li et al., 2016a). The previous studies demonstrated that the cannabinoid agonists, including WIN 55,212-2, Δ9-tetrahydrocannabinol and anandamide, produced highly significant analgesic effects against acute and inflammatory pain induced by plantar injection of formalin, and markedly suppressed pain-evoked c-Fos expression in the spinal dorsal horn in the immunocytochemical experiments (Borsani et al., 2007; Jaggar et al., 1998; Moss and Johnson, 1980; Tsou et al., 1996). The present work indicated that i.c.v. injection of WIN 55,212-2 significantly reduced formalin-induced pain behavior in mice, which was reversed by the CB1 antagonist/inverse agonist AM251, but not the CB2 receptor antagonist AM630.

  • Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain

    2014, European Journal of Pharmacology
    Citation Excerpt :

    The i.p. administration of THC did not induce motor impairment at the doses of 1 and 3 mg/kg, but locomotor activity was significantly reduced with the administration of 5 mg/kg [F(3, 19)=6.274, P=0.0039] (Fig. 5). THC has shown to exert an antinociceptive effect in a wide range of preclinical acute nociception tests as the acetic acid model (Booker et al., 2009), tail flick test (Mason et al., 1999) or paw pressure test (Smith et al., 1998; Tseng and Craft, 2001), and also in chronic pain assays as inflammatory pain (Moss and Johnson, 1980; Takahashi et al., 2003), arthritic pain (Cox et al., 2007) or neuropathic pain (De Vry et al., 2004). Now, we show the effect of THC in two models of muscle pain and to our knowledge the results from this study are the first to demonstrate the efficacy of THC in animal models of acute muscle pain.

  • The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain

    2013, Neuroscience
    Citation Excerpt :

    CB1 receptors are associated with the peripheral and central nervous systems whereas CB2 receptors are primarily located on immune cells (Munro et al., 1993; Facci et al., 1995; Galiegue et al., 1995). Cannabinoid receptor agonists have been shown to reduce hyperalgesia in animal models of inflammatory (Moss and Johnson, 1980; Calignano et al., 1998; Richardson et al., 1998b; Martin et al., 1999; Clayton et al., 2002; Elmes et al., 2005), neuropathic (Herzberg et al., 1997; Bridges et al., 2001; Fox et al., 2001; Ibrahim et al., 2003), capsaicin (Richardson et al., 1998a,b; Ko and Woods, 1999; Li et al., 1999; Johanek et al., 2001; Rukwied et al., 2003) and cancer pain (Kehl et al., 2003; Hamamoto et al., 2007; Hald et al., 2008; Potenzieri et al., 2008a; Khasabova et al., 2011). Importantly, administration of cannabinoids into the tumor-bearing paw decreased mechanical hyperalgesia through activation of cannabinoid receptors located in the periphery (Potenzieri et al., 2008b; Khasabova et al., 2011), suggesting that cannabinoids decreased mechanically evoked responses of nociceptors.

  • Involvement of descending serotonergic and noradrenergic pathways in CB<inf>1</inf> receptor-mediated antinociception

    2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    Citation Excerpt :

    It is suggested that cannabinoids may have a neurotransmitter or neuromodulator function within the central nervous system, and there is now considerable evidence supporting a role for cannabinoids in modulating nociception (Pertwee, 2001). The naturally occurring Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids such as WIN 55,212-2 and putative endocannabinoids such as anandamide and 2-arachinoylglycerol (2-AG) have been shown to exert antinociceptive action in preclinical experimental pain models, including forms of acute, inflammatory and neuropathic pain (Dogrul et al., 2002, 2004; Gunduz et al., 2011; Herzberg et al., 1997; Hohmann and Suplita, 2006; Martin et al., 1993; Moss and Johnson, 1980; Rea et al., 2007; Richardson et al., 1998; Sofia et al., 1973; Staahl et al., 2009; Ulugol et al., 2004, 2006). Cannabinoids produced analgesic effects in the clinical studies of human volunteers and pain patients (Burgess and Williams, 2010; Hosking and Zajicek, 2008; Russo, 2008).

View all citing articles on Scopus
View full text